Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4A
|
pubmed:dateCreated |
1991-11-8
|
pubmed:abstractText |
Estrone sulfatase is an important mechanism of local synthesis of biologically active estrogens in human breast cancer. The human placental microsome and breast carcinoma mitochondrial/microsomal estrone sulfatase activity were characterized and inhibition studies performed. The Km of the placental tissue enzyme was 6.83 microM, Vmax 0.015 nmol/min/mg, and for the breast carcinoma tissue Km was 8.91 microM and Vmax 0.022 nmol/min/mg. Danazol produced a significant inhibition of estrone sulfatase (20% with 50 microM danazol). No significant inhibition was seen in the presence of aminoglutethimide, rogletimide, tamoxifen, 4-hydroxyandrostenedione, stilboestrol, or any metabolites of danazol or tamoxifen. Studies with synthetic and naturally occurring steroids demonstrated that the presence of a sulfate group at the 3 position to be the most important factor in determining inhibition, and the most potent inhibitor was 5 alpha-androstene-3 beta,17 beta-diol-3-sulfate (Ki of 2.0 microM). The naturally occurring 3-sulfated steroids all demonstrated competitive inhibition. These studies could form the basis for the design of a potent estrone sulfatase inhibitor which would have potential therapeutic activity in the management of breast cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androgens,
http://linkedlifedata.com/resource/pubmed/chemical/Danazol,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogens,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfatases,
http://linkedlifedata.com/resource/pubmed/chemical/estrone sulfatase
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0960-0760
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
493-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1911438-Androgens,
pubmed-meshheading:1911438-Breast Neoplasms,
pubmed-meshheading:1911438-Cell Nucleus,
pubmed-meshheading:1911438-Danazol,
pubmed-meshheading:1911438-Estrogen Antagonists,
pubmed-meshheading:1911438-Estrogens,
pubmed-meshheading:1911438-Female,
pubmed-meshheading:1911438-Humans,
pubmed-meshheading:1911438-Kinetics,
pubmed-meshheading:1911438-Microsomes,
pubmed-meshheading:1911438-Mitochondria,
pubmed-meshheading:1911438-Placenta,
pubmed-meshheading:1911438-Pregnancy,
pubmed-meshheading:1911438-Substrate Specificity,
pubmed-meshheading:1911438-Sulfatases
|
pubmed:year |
1991
|
pubmed:articleTitle |
Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinoma.
|
pubmed:affiliation |
Department of Medical Oncology, Charing Cross Hospital, London, England.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|